Blindness News and Research

RSS

In-school education programs can reduce obesity, other risk factors for type 2 diabetes: HEALTHY

Healthier cafeteria choices, longer and more intense periods of physical activity and robust in-school education programs can lower rates of obesity and other risk factors for type 2 diabetes, according to a national study called HEALTHY.

28 Jun 2010

HQC report presents different aspects of health care delivered in Saskatchewan hospitals

There's been little change over the last three years in how patients rate the care they receive in Saskatchewan hospitals, according to a report released today by the province's Health Quality Council. The report, entitled Quality Insight 2010, presents an overview of aspects of quality of care delivered in hospitals, in the community for people living with certain chronic diseases, and for seniors taking prescription drugs.

25 Jun 2010

NKI awarded Phase II SBIR grant to develop new ophthalmic screening device for diabetic retinopathy

Neuro Kinetics, Inc., manufacturers of noninvasive medical diagnostic equipment used worldwide to test for vestibular and neurological conditions, said today that it has been awarded a Phase II Small Business Innovation Research grant to further the company's development of a new ophthalmic screening device and testing protocols for the detection and diagnosis of diabetic retinopathy.

25 Jun 2010

New research suggests resveratrol may inhibit pathogenic blood vessel formation

Current research suggests that resveratrol, a naturally occurring compound found in red wine, grapes, blueberries, peanuts, and other plants, inhibits pathogenic new blood vessel growth.

25 Jun 2010

Cellonis' stem cells diabetes treatment helps reconstruct natural insulin production

Cellonis, a Beijing and HK-based biotech company, with its new personalized diabetes treatment concept has demonstrated an amazing improvement in their treated patients' conditions. The ongoing clinical study shows the treatment's best case could reconstruct a patient's natural insulin production and even reverse later complications like kidney failure. Treated patients may have the chance to return to the normal activities non-diabetes sufferers take for granted.

24 Jun 2010

Merck proposes to initiate Phase II proof-of-concept clinical study of posaconazole for chronic Chagas disease

Merck today announced plans to initiate a Phase II investigational proof-of-concept clinical study to evaluate its oral antifungal agent posaconazole for the treatment of chronic Chagas disease. Chagas disease results from infection with the parasite Trypanosoma cruzi that is spread by biting insects. The disease is estimated to affect approximately eight million people in Latin America, of whom approximately 30-40 percent will develop serious cardiac disease, digestive disease, or both as a result of this infection.

24 Jun 2010

AGTC, Icagen complete agreement for purchase and sale of patent rights

AGTC, a privately held company, and Icagen, Inc. today announced the completion of an agreement for the purchase and sale of certain patent rights between the companies. Icagen is transferring its rights to patents relating to the ion channel gene CNGB3, which has been linked to certain disorders of the eye. Under the terms of the agreement, Icagen has assigned ownership of the patents to AGTC, which intends to use the patented technology for gene therapy as a potential treatment for Achromatopsia, a severe form of daytime blindness.

24 Jun 2010

International Stem Cell congratulates ACT on the issuance of its recent patent

International Stem Cell Corporation, www.intlstemcell.com, a California-based biotechnology company focused on therapeutic and research products, congratulates Advanced Cell Technology, Inc. on the issuance of its recent patent, U.S. Patent Number 7,736,896, covering a method for producing retinal pigment epithelial cells.

24 Jun 2010

Debiotech, STMicroelectronics to showcase novel insulin "Jewel Pump" at ADA Congress

Debiotech and STMicroelectronics today announced that they will publicly showcase their novel insulin "Jewel Pump" at the Debiotech stand at the American Diabetes Association 70th Scientific Sessions (June 25-29) in Orlando, Florida.

24 Jun 2010

Dapagliflozin as monotherapy demonstrates potential for type 2 diabetes treatment

Findings from a 24-week Phase 3 clinical study published online in the latest issue of Diabetes Care demonstrated that the investigational drug dapagliflozin, administered as a monotherapy, achieved statistically significant mean reductions at 5 mg and 10 mg doses once daily in the primary endpoint of glycosylated hemoglobin levels (HbA1c) in treatment-naïve adult patients with newly diagnosed type 2 diabetes, compared to placebo.

23 Jun 2010

European drugmakers lead in making medicines available to developing world, Index says

European drug companies came out ahead of their U.S. counterparts in making medicines available to people in developing countries, but their lead is beginning to shrink, according to the Access to Medicines Index, released on Monday, Reuters reports (Kelland, 6/21).

23 Jun 2010

QLT reports final 24-month results from Phase II RADICAL study in patients with wet AMD

QLT Inc. today announced final 24-month results from the Phase II RADICAL study (Reduced Fluence Visudyne Anti-VEGF-Dexamethasone In Combination for AMD Lesions) in patients with exudative (wet) age-related macular degeneration. The purpose of the study was to determine if Visudyne® combined with Lucentis® reduced retreatment rates compared with Lucentis monotherapy, while maintaining similar vision outcomes and an acceptable safety profile.

22 Jun 2010

APP Pharmaceuticals receives FDA approval to market Ganciclovir for Injection, USP

APP Pharmaceuticals, Inc., a wholly owned subsidiary of Fresenius Kabi Pharmaceuticals Holding, Inc., announced today that it has received approval from the U.S. Food and Drug Administration to market Ganciclovir for Injection, USP. Ganciclovir for Injection, USP is therapeutically equivalent to the reference-listed drug Cytovene-IV, which is marketed by Roche Laboratories, Inc.

22 Jun 2010

Discoveries in study and manipulation of human ES cells win first prize in research competition

World-recognized discoveries in the study and manipulation of human embryonic stem cells have won first prize in a prestigious applied research competition for a Hebrew University of Jerusalem researcher.

22 Jun 2010

Blind cyclists to travel from Toronto to Collingwood in support of the Foundation Fighting Blindness

On Saturday, June 19th, the vision impaired community will team up with cycling enthusiasts to embark on a 140 km journey for second annual Cycle for Sight, in support of the Foundation Fighting Blindness.

19 Jun 2010

WSJ: Study on eye medicine reveals possible savings for Medicare

The Wall Street Journal reports that Medicare could save $500 million a year by switching from one type of eye medicine to another, both made by Genentech, "according to a draft study by federal officials and a University of Miami eye doctor.

18 Jun 2010

First clinical trial results of XOMA 052 in patients with uveitis of Behcet's disease presented at EULAR 2010

XOMA Ltd., a leader in the discovery and development of therapeutic antibodies, announced positive results from an open-label pilot study of XOMA 052 in patients with uveitis of Behcet's disease who were suffering from vision-threatening exacerbations despite maximal doses of immunosuppressive medicines.

17 Jun 2010

Researchers use computer-based model to study human visual intelligence

Scientists have just come several steps closer to understanding change blindness - the well studied failure of humans to detect seemingly obvious changes to scenes around them - with new research that used a computer-based model to predict what types of changes people are more likely to notice.

17 Jun 2010

Final results from Visudyne Phase IIIb DENALI study presented at World Ophthalmology Congress

QLT Inc. today announced that final results from the Novartis-sponsored Phase IIIb DENALI study were presented on June 8, 2010 during the World Ophthalmology Congress in Berlin. DENALI was a 24-month randomized, double-masked, multicenter trial in patients with subfoveal choroidal neovascularization secondary to wet age-related macular degeneration (all lesion types).

16 Jun 2010

UH, AOA partner to get the word out about summer eye care, protection against UVR

As summer approaches, most people step up skin protection from harmful ultraviolet rays, yet aren't as vigilant about their eyes. Optometrists at the University of Houston are involved in a campaign to change this way of thinking.

15 Jun 2010

Blindness News and Research

In-school education programs can reduce obesity, other risk factors for type 2 diabetes: HEALTHY

HQC report presents different aspects of health care delivered in Saskatchewan hospitals

NKI awarded Phase II SBIR grant to develop new ophthalmic screening device for diabetic retinopathy

New research suggests resveratrol may inhibit pathogenic blood vessel formation

Cellonis' stem cells diabetes treatment helps reconstruct natural insulin production

Merck proposes to initiate Phase II proof-of-concept clinical study of posaconazole for chronic Chagas disease

AGTC, Icagen complete agreement for purchase and sale of patent rights

International Stem Cell congratulates ACT on the issuance of its recent patent

Debiotech, STMicroelectronics to showcase novel insulin "Jewel Pump" at ADA Congress

Dapagliflozin as monotherapy demonstrates potential for type 2 diabetes treatment

European drugmakers lead in making medicines available to developing world, Index says

QLT reports final 24-month results from Phase II RADICAL study in patients with wet AMD

APP Pharmaceuticals receives FDA approval to market Ganciclovir for Injection, USP

Discoveries in study and manipulation of human ES cells win first prize in research competition

Blind cyclists to travel from Toronto to Collingwood in support of the Foundation Fighting Blindness

WSJ: Study on eye medicine reveals possible savings for Medicare

First clinical trial results of XOMA 052 in patients with uveitis of Behcet's disease presented at EULAR 2010

Researchers use computer-based model to study human visual intelligence

Final results from Visudyne Phase IIIb DENALI study presented at World Ophthalmology Congress

UH, AOA partner to get the word out about summer eye care, protection against UVR

Industry Focus eBook - Life Science Microscopy (2nd Edition) eBook

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News